N2MO has been granted European (EPO) Patent for Screening Methods employing insects with Blood Brain Barrier

The patent covers insect models that are aimed to reflect vertebrate blood-brain barrier (BBB) penetration.

The value of the insect BBB model is that it can be just as predictive as expensive and time consuming animal models, and by using the insect BBB model the identification of “false negatives” and “false positives” can be achieved at a very early stage in the drug discovery development.

N2MO has already introduced an ex vivo BBB insect model to the market and is today collaborating with several leading pharmaceutical companies